Cetrorelix in the treatment of female infertility and endometriosis (Q34571550)

3 August 2017

1 reference

title

Cetrorelix in the treatment of female infertility and endometriosis (English)

1 reference

3 August 2017

1 reference

2

Daniela Hornung

1 reference

3 August 2017

Dominique Finas

1

1 reference

3 August 2017

Klaus Diedrich

series ordinal

3

1 reference

3 August 2017

Askan Schultze-Mosgau

series ordinal

4

1 reference

3 August 2017

language of work or name

English

0 references

publication date

1 October 2006

1 reference

Expert Opinion on Pharmacotherapy

3 August 2017

1 reference

3 August 2017

7

1 reference

3 August 2017

15

1 reference

3 August 2017

2155-2168

1 reference

Reproductive/endocrine and anaphylactoid properties of an LHRH-antagonist, ORF 18260 [Ac-DNAL1(2), 4FDPhe2,D-Trp3,D-Arg6]-GnRH.

3 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2155

GnRH antagonists in the treatment of infertility

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2155

The efficacy of medical and surgical treatment of endometriosis-associated infertility and pelvic pain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2155

Increased pregnancy rates after ultralong postoperative therapy with gonadotropin-releasing hormone analogs in patients with endometriosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2155

Use of GnRH antagonists in ovarian stimulation for assisted reproductive technologies compared to the long protocol. Meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2155

Significant reduction of the incidence of ovarian hyperstimulation syndrome (OHSS) by using the LHRH antagonist Cetrorelix (Cetrotide) in controlled ovarian stimulation for assisted reproduction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2155

Ovarian stimulation with HMG: results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin. European Cetrorelix Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2155

Ovarian stimulation for assisted reproduction with HMG and concomitant midcycle administration of the GnRH antagonist cetrorelix according to the multiple dose protocol: a prospective uncontrolled phase III study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2155

Prospective, randomized, controlled study of in vitro fertilization-embryo transfer with a single dose of a luteinizing hormone-releasing hormone (LH-RH) antagonist (cetrorelix) or a depot formula of an LH-RH agonist (triptorelin).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2155

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2155

Gonadotropin-releasing-hormone-receptor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2155

Use of GnRH antagonists in the treatment of endometriosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2155

Management of endometriosis-associated infertility

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2155

Gonadotropin-releasing hormone antagonists: impact of IVF practice and potential non-assisted reproductive technology applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2155

Hormone profiles under ovarian stimulation with human menopausal gonadotropin (hMG) and concomitant administration of the gonadotropin releasing hormone (GnRH)-antagonist Cetrorelix at different dosages.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2155

Embryo implantation and GnRH antagonists: ovarian actions of GnRH antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2155

GnRH antagonist in assisted reproduction: a Cochrane review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2155

Optimal stimulation protocols for in vitro fertilization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2155

Actions of gonadotropin-releasing hormone antagonists on steroidogenesis in human granulosa lutein cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2155

Recovery of pituitary-gonadal function in male and female rats after prolonged administration of a potent antagonist of luteinizing hormone-releasing hormone (SB-75).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2155

Assessment of luteinizing hormone level in the gonadotropin-releasing hormone antagonist protocol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2155

Plasma and follicular fluid concentrations of LHRH antagonist cetrorelix (Cetrotide) in controlled ovarian stimulation for IVF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2155

Revised American Society for Reproductive Medicine classification of endometriosis: 1996

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2155

Safety and efficacy of a 3 mg dose of the GnRH antagonist cetrorelix in preventing premature LH surges: report of two large multicentre, multinational, phase IIIb clinical experiences

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2155

Luteal estradiol pre-treatment coordinates follicular growth during controlled ovarian hyperstimulation with GnRH antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2155

Prospective, randomized trial comparing cetrorelix acetate and ganirelix acetate in a programmed, flexible protocol for premature luteinizing hormone surge prevention in assisted reproductive technologies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2155

Health of 227 children born after controlled ovarian stimulation for in vitro fertilization using the luteinizing hormone-releasing hormone antagonist cetrorelix

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2155

The LHRH antagonist cetrorelix: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2155

Clinical application of GnRH-antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2155

Antiproliferative effects of the GnRH antagonist cetrorelix and of GnRH-II on human endometrial and ovarian cancer cells are not mediated through the GnRH type I receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2155

GnRH antagonists in the treatment of gynecological and breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2155

Phase II study of cetrorelix, a luteinizing hormone-releasing hormone antagonist in patients with platinum-resistant ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2155

Effect of cetrorelix acetate on apoptosis and apoptosis regulatory factors in cultured uterine leiomyoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2155

Population pharmacokinetic modeling of a subcutaneous depot for GnRH antagonist degarelix

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2155

Development of GnRH antagonists for prostate cancer: new approaches to treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2155

Pharmacokinetics and pharmacodynamics of a novel depot formulation of abarelix, a gonadotropin-releasing hormone (GnRH) antagonist, in healthy men ages 50 to 75.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2155

GnRH antagonists: present and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2155

Systemic delivery of cetrorelix to rats by a new aerosol delivery system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2155

Biological characterization of a novel, orally active small molecule gonadotropin-releasing hormone (GnRH) antagonist using castrated and intact rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2155

Non-peptidic GnRH receptor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2155

Suppression of a pituitary-ovarian axis by chronic oral administration of a novel nonpeptide gonadotropin-releasing hormone antagonist, TAK-013, in cynomolgus monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2155

Emerging drugs in assisted reproduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2155

10.1517/14656566.7.15.2155

21 January 2018

Identifiers

DOI

1 reference

3 August 2017

1 reference